These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

665 related articles for article (PubMed ID: 26884586)

  • 1. Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression.
    Burstein HJ; Lacchetti C; Anderson H; Buchholz TA; Davidson NE; Gelmon KE; Giordano SH; Hudis CA; Solky AJ; Stearns V; Winer EP; Griggs JJ
    J Clin Oncol; 2016 May; 34(14):1689-701. PubMed ID: 26884586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update.
    Burstein HJ; Lacchetti C; Anderson H; Buchholz TA; Davidson NE; Gelmon KA; Giordano SH; Hudis CA; Solky AJ; Stearns V; Winer EP; Griggs JJ
    J Clin Oncol; 2019 Feb; 37(5):423-438. PubMed ID: 30452337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Standards, Options and Recommendations (SOR) for endocrine therapy in patients with non metastatic breast cancer. FNCLCC].
    Mauriac L; Blanc-Vincent MP; Luporsi E; Cutuli B; Fourquet A; Garbay JR; Giard S; Spyratos F; Zafrani B; Dilhuydy JM
    Bull Cancer; 2000 Jun; 87(6):469-90. PubMed ID: 10903789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.
    Burstein HJ; Prestrud AA; Seidenfeld J; Anderson H; Buchholz TA; Davidson NE; Gelmon KE; Giordano SH; Hudis CA; Malin J; Mamounas EP; Rowden D; Solky AJ; Sowers MR; Stearns V; Winer EP; Somerfield MR; Griggs JJ;
    J Clin Oncol; 2010 Aug; 28(23):3784-96. PubMed ID: 20625130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.
    Winer EP; Hudis C; Burstein HJ; Wolff AC; Pritchard KI; Ingle JN; Chlebowski RT; Gelber R; Edge SB; Gralow J; Cobleigh MA; Mamounas EP; Goldstein LJ; Whelan TJ; Powles TJ; Bryant J; Perkins C; Perotti J; Braun S; Langer AS; Browman GP; Somerfield MR
    J Clin Oncol; 2005 Jan; 23(3):619-29. PubMed ID: 15545664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update.
    Burstein HJ; Temin S; Anderson H; Buchholz TA; Davidson NE; Gelmon KE; Giordano SH; Hudis CA; Rowden D; Solky AJ; Stearns V; Winer EP; Griggs JJ
    J Clin Oncol; 2014 Jul; 32(21):2255-69. PubMed ID: 24868023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant endocrine therapy for premenopausal women with hormone-responsive breast cancer.
    Mathew A; Davidson NE
    Breast; 2015 Nov; 24 Suppl 2():S120-5. PubMed ID: 26255743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of ovarian function suppression in premenopausal women with estrogen receptor-positive early breast cancer.
    Lambertini M; Viglietti G; de Azambuja E
    Curr Opin Oncol; 2019 Jan; 31(1):43-51. PubMed ID: 30299291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Role of Ovarian Suppression in Premenopausal Women With Hormone Receptor-Positive Early-Stage Breast Cancer.
    Jain S; Santa-Maria CA; Gradishar WJ
    Oncology (Williston Park); 2015 Jul; 29(7):473-8, 481. PubMed ID: 26178334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aromatase inhibitor plus ovarian suppression as adjuvant therapy in premenopausal women with breast cancer.
    Figg WD; Cook K; Clarke R
    Cancer Biol Ther; 2014; 15(12):1586-7. PubMed ID: 25535893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant endocrine therapy in hormone receptor-positive postmenopausal breast cancer: evolution of NCCN, ASCO, and St Gallen recommendations.
    Carlson RW; Hudis CA; Pritchard KI; ; ;
    J Natl Compr Canc Netw; 2006 Nov; 4(10):971-9. PubMed ID: 17112447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ovarian suppression in combination endocrine adjuvant therapy in premenopausal women with early breast cancer.
    Chlebowski RT; Pan K; Col NF
    Breast Cancer Res Treat; 2017 Jan; 161(2):185-190. PubMed ID: 27785653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
    Francis PA; Pagani O; Fleming GF; Walley BA; Colleoni M; Láng I; Gómez HL; Tondini C; Ciruelos E; Burstein HJ; Bonnefoi HR; Bellet M; Martino S; Geyer CE; Goetz MP; Stearns V; Pinotti G; Puglisi F; Spazzapan S; Climent MA; Pavesi L; Ruhstaller T; Davidson NE; Coleman R; Debled M; Buchholz S; Ingle JN; Winer EP; Maibach R; Rabaglio-Poretti M; Ruepp B; Di Leo A; Coates AS; Gelber RD; Goldhirsch A; Regan MM;
    N Engl J Med; 2018 Jul; 379(2):122-137. PubMed ID: 29863451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant endocrine therapy for premenopausal women: risk stratification, type and duration.
    Francis PA
    Breast; 2019 Nov; 48 Suppl 1():S85-S88. PubMed ID: 31839169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant ovarian function suppression and tamoxifen in premenopausal breast cancer patients: A meta-analysis.
    Azim HA; Shohdy KS; Kaldas DF; Kassem L; Azim HA
    Curr Probl Cancer; 2020 Dec; 44(6):100592. PubMed ID: 32527567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal adjuvant endocrine therapy for early breast cancer.
    Stuart-Harris R; Davis A
    Womens Health (Lond); 2010 May; 6(3):383-98. PubMed ID: 20426605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer.
    Jankowitz RC; McGuire KP; Davidson NE
    Breast; 2013 Aug; 22 Suppl 2():S165-70. PubMed ID: 24074781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Navigating the Challenges of Endocrine Treatments in Premenopausal Women with ER-Positive Early Breast Cancer.
    Colleoni M; Munzone E
    Drugs; 2015 Aug; 75(12):1311-21. PubMed ID: 26177891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant ovarian suppression in premenopausal breast cancer.
    Francis PA; Regan MM; Fleming GF; Láng I; Ciruelos E; Bellet M; Bonnefoi HR; Climent MA; Da Prada GA; Burstein HJ; Martino S; Davidson NE; Geyer CE; Walley BA; Coleman R; Kerbrat P; Buchholz S; Ingle JN; Winer EP; Rabaglio-Poretti M; Maibach R; Ruepp B; Giobbie-Hurder A; Price KN; Colleoni M; Viale G; Coates AS; Goldhirsch A; Gelber RD; ;
    N Engl J Med; 2015 Jan; 372(5):436-46. PubMed ID: 25495490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant systemic therapy for women with node-positive breast cancer. The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.
    CMAJ; 1998 Feb; 158 Suppl 3():S52-64. PubMed ID: 9484279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.